Activation of AMP-Activated Protein Kinase by 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribonucleoside Prevents Leucine-Stimulated Protein Synthesis in Rat Skeletal Muscle1,2

Anne M. Pruznak, Abid A. Kazi, Robert A. Frost, Thomas C. Vary, and Charles H. Lang*

Department of Cellular and Molecular Physiology, Pennsylvania State College of Medicine, Hershey, PA 17033

Abstract

Several stress conditions are characterized by activation of 5'-AMP-activated protein kinase (AMPK) and the development of leucine resistance in skeletal muscle. In the present study, we determined whether direct activation of the AMPK by 5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside (AICAR) prevents the characteristic leucine-induced increase in protein synthesis by altering mammalian target of rapamycin (mTOR) signal transduction. Rats were injected with AICAR or saline (Sal) and 1 h thereafter received an oral gavage of leucine (or Sal). Efficacy of AICAR was verified by increased AMPK phosphorylation. AICAR decreased basal in vivo muscle (gastrocnemius) protein synthesis and completely prevented the leucine-induced increase, independent of a change in muscle adenine nucleotide concentration. AICAR also prevented the hyperphosphorylation of eukaryotic initiation factor (eIF) 4E binding protein (4E-BP1), ribosomal protein S6 kinase (S6K1), S6, and elf4G in response to leucine, suggesting a decrease in mTOR activity. Moreover, AICAR prevented the leucine-induced redistribution of elf4E from the inactive elf4E-4E-BP1 to the active elf4E-elf4G complex. This ability of AICAR to produce muscle leucine resistance could not be attributed to a change in phosphorylation of tuberous sclerosis complex (TSC)2, the formation of a TSC1-TSC2 complex, the binding of raptor with mTOR, or the phosphorylation of eukaryotic elongation factor-2. However, the inhibitory actions of AICAR were associated with reduced phosphorylation of proline-rich Akt substrate-40 and increased phosphorylation of raptor, which represent potential mechanisms by which AICAR might be expected to inhibit leucine-induced increases in mTOR activity and protein synthesis under in vivo conditions. J. Nutr. 138: 1887–1894, 2008.

Introduction

The rate of muscle protein synthesis is controlled by the capacity (e.g., abundance of ribosomes and mRNA) and efficiency (e.g., initiation, elongation, and termination) of the synthetic pathway. Several stress conditions, exemplified by sepsis and the related condition of endotoxemia, decrease muscle protein synthesis principally by slowing the rate of peptide-chain initiation (1). This impairment is mediated by a decrease in the kinase activity of mammalian target of rapamycin (mTOR),3 as assessed by reduced phosphorylation of the downstream substrates eukaryotic initiation factor (eIF)-4E binding protein (4E-BP1) and the 70-kDa ribosomal protein S6 kinase (S6K1) (2–5). The canonical mTOR signaling pathway integrates nutrient, hormonal signals, and the intracellular energy state to control mRNA translation. Furthermore, several stresses (e.g., sepsis, alcohol intoxication, glucocorticoid excess) not only decrease the constitutive rate of muscle protein synthesis but also acutely limit the normal anabolic response to the branched-chain amino acid leucine, an effect partially mediated by an inability to activate mTOR (3,6–10).

The 5'-AMP-activated protein kinase (AMPK) is an important sensor for monitoring cellular energy status (11). AMPK regulates carbohydrate, lipid, and protein metabolism in muscle via its effects on multiple signaling pathways and thereby suppresses ATP-demanding processes and activates ATP-repleting pathways. The acute metabolic consequences of AMPK activation on protein balance are mediated in part by the tuberous sclerosis complex (TSC)1 gene product and TSC2, which are upstream of mTOR (12). Both increased TSC2 phosphorylation, and upstream formation of the TSC1-TSC2 heterodimer can

1 Supported by NIH grants GM38032, AA 11290 (C.H.L.), and GM39277 (T.C.V.).
3 Abbreviations used: AICAR, 5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside; AMPK, 5'-AMP-activated protein kinase; CP, creatine phosphate; 4E-BP1, eukaryotic initiation factor 4E binding protein-1; eEF, eukaryotic elongation factor; elf4E, eukaryotic elongation factor; GβL, G protein β-subunit-like protein; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; PRAS40, proline-rich Akt substrate 40; Sal, saline; S6K1, 70-kDa ribosomal protein S6 kinase; TSC, tuberous sclerosis complex.
4 To whom correspondence should be addressed. E-mail: clang@psu.edu.

0222-3166/08 $8.00 © 2008 American Society for Nutrition.

negatively regulate mTOR activity (12,13). In addition, AMPK activation regulates gene expression of metabolic pathways influencing protein balance (14,15).

A variety of cellular stressors, including 2-deoxyglucose, nutrient deprivation, and exercise, activate AMPK by raising the cellular AMP:ATP ratio. In addition, AMPK can also be activated without altering endogenous adenine nucleotide concentration by the pharmacological agent 5-aminomidazole-4-carboxamide-1-β-D-ribonucleoside (AICAR) (11). Administration of AICAR in vivo blunts the anabolic actions of electrical stimulation in skeletal muscle (16) and the cardiac hypertrophy produced by pressure overload (17). Similarly, because AMPK is an obligate effector of many cellular responses to nutrient limitation, its activation may blunt the ability of the branched-chain amino leucine to stimulate protein synthesis. In this regard, during the preparation of this manuscript, Du et al. (18) reported that incubation of C2C12 myoblasts with AICAR prevented leucine-induced phosphorylation of mTOR and S6K1.

In general, both AICAR and leucine appear to have their effect on skeletal muscle predominantly via alterations in mTOR signaling as opposed to altering the elf2βB system and the formation of 43S preinitiation complex (19–21). Therefore, the current in vivo study focused on the ability of AICAR to modulate the anabolic effects of leucine by regulating steps in peptide-chain initiation involving the binding of mRNA to the 43S preinitiation complex, which is mediated by a functional elf4F complex. Accordingly, we tested the hypothesis that direct AMPK activation by AICAR attenuates or prevents the ability of leucine to stimulate in vivo protein synthesis via inhibition of mTOR activity in skeletal muscle.

Materials and Methods

Animal preparation and experimental protocol. The animal protocol was approved by the Institutional Animal Care and Use Committee of The Pennsylvania State University College of Medicine and adheres to the NIH guidelines for the use of experimental animals. Specific pathogen-free male Sprague-Dawley rats (175–200 g; Charles River Breeding Laboratories) were housed in a controlled environment and consumed food (Harlan Teklad no. 2018 rodent diet) and water ad libitum for 1 wk before the start of the study. The commercial diet consisted of ~18% protein, 6% fat, and 3.8% fiber.

On the morning of the study, food was removed and rats were injected subcutaneously with AICAR (1 mg/g body weight; Toronto Research Chemicals) to stimulate AMPK. Time-matched control rats were injected with an equal volume of vehicle [sterile 0.9% saline (Sal)]. Rats were orally gavaged with leucine (1.35 g/kg body weight) or an equal volume of Sal 60 min after AICAR. Hence, this study contained 4 experimental groups: Sal + Sal, Sal + Leu (leucine), AICAR + Sal, and AICAR + Leu. The average body weight did not differ among the groups (data not shown). The dose and timing for AICAR were selected, because they have been reported to decrease basal muscle protein synthesis (20) and the leucine protocol shown to maximally stimulate muscle protein synthesis via increases in mTOR activity and cap-dependent translation (3,8,19,22).

After leucine gavage, rats were anesthetized with intraperitoneal pentobarbital and a catheter inserted into the carotid artery for blood collection. Exactly 20 min after leucine gavage, protein synthesis was determined using the flooding-dose method (23). Rats were injected with 1[3H]phenylalanine (Phe; 150 mmol/L, 30 mCi/L; 1 mL/100 g body weight) via the jugular vein and arterial blood collected into heparinized syringes at 2, 6, and 10 min for measurement of plasma Phe-specific radioactivity. Thereafter, a portion of the representative fast-twitch gastrocnemius was freshly homogenized and the remainder freeze-clamped and stored at ~70°C. Muscle was powdered under liquid nitrogen and a portion used to estimate the rate of incorporation of [3H]Phe into protein, exactly as previously described (3,5,24).

Plasma hormones and tissue adenine nucleotides. Prior to the injection of [3H]Phe, arterial blood was collected and the plasma used to determine insulin (Linco Research), total insulin-like growth factor-I (Immunodiagnostic Systems Limited), and testosterone (DSL) by ELISA. Branched-chain amino acids were determined using reverse-phase HPLC after precolumn derivatization of amino acids with phenylisothiocyanate. Powdered gastrocnemius was extracted in cold perchloric acid, neutralized, and used for the determination of ATP, AMP, and creatine phosphate (CP) by standard fluorometric methods (25).

Immunoprecipitation and Western blot analysis. The tissue preparation was the same as described by our laboratories (1–3,6,8,26). A muscle homogenate was prepared using a 1:5 ratio of ice-cold homogenization buffer consisting of (in mmol/L) 20 HEPEs, pH 7.4, 2 EDTA, 50 NaF, 100 KCl, 0.2 EDTA, 50 β-glycerophosphate, 1 dithiothreitol, 0.1 phenyl-methylsulphonyl fluoride, 1 benzamidine, and 0.5 sodium vanadate, plus a protease inhibitor cocktail page from Roche, and clarified by centrifugation. The samples were subjected to SDS-PAGE and the proteins electrophoretically transferred to polyvinylidene difluoride membranes. The blots were incubated with either primary antibodies (unless otherwise noted from Cell Signaling) to total (C-20) and Thr1462-phosphorylated TSC2, total G protein β-subunit-like protein (GβL; mLST8), total and phosphorylated (Ser792) raptor, total S6K1 (Santa Cruz Biotechnology), phospho-specific S6K1 (Thr389), total 4E-BP1 (Bethyl Laboratories), phospho-specific 4E-BP1 (Thr37/46), total and phosphorylated (Ser1108) elf4F, total and phosphorylated-S6 (Ser240/Ser244), and total and phosphorylated (Thr56) eukaryotic elongation factor (eEF)-2, and total and phosphorylated (Thr246) proline-activated Akt substrate 40 (PRAS40) (Biosource). In addition, we determined activation of AMPK, total and phosphorylated AMPKα (Thr172) and acetyl-CoA carboxylase (Ser79) were used (14). Blots were washed with 1% Tris-buffered Sal including 0.1% Tween-20 and incubated with secondary antibody (horseradish peroxidase conjugated goat anti-mouse or goat anti-rabbit) IgG at room temperature. The blots were developed with enhanced chemiluminescence Western blotting reagents, as per the manufacturer’s (Amersham) instructions, and exposed to X-ray film in a cassette equipped with a DuPont Lightning Plus intensifying screen. After development, the film was scanned (Microtek ScanMaker IV) and analyzed using NIH Image 1.6 software.

The elf4F-4E-BP1 and elf4E-elf4F complexes were quantified as described (3,6,8,26). From an aliquot of supernatant, elf4E was immunoprecipitated using an anti-elf4E monoclonal antibody (kindly provided by Drs. Jefferson and Kimball, Pennsylvania State College of Medicine). Antibody-antigen complexes were collected using magnetic beads, subjected to SDS-PAGE, and proteins transferred to a PVDF membrane. Blots were incubated with a mouse anti-human elf4E antibody, rabbit anti-rat 4E-BP1 antibody, or rabbit anti-elf4F antibody.

To maintain protein-protein interaction, muscle samples were homogenized in CHAPS buffer consisting of (in mmol/L) 40 HEPEs, pH7.5, 120 NaCl, 1 EDTA, 10 pyrophosphate, 10 β-glycerophosphate, 50 NaF, 1.5 sodium vanadate, 0.5% CHAPS, and 1 protease inhibitor cocktail tablet. The homogenate was mixed on a platform rocker and clarified by centrifugation. An aliquot of the resulting supernatant was combined with either anti-TSC2, anti-mTOR, or anti-raptor antibody and immune complexes isolated with magnetic beads, subjected to SDS-PAGE, and proteins transferred to a PVDF membrane. Blots were incubated with a mouse anti-human elf4E antibody, rabbit anti-rat 4E-BP1 antibody, or rabbit anti-elf4F antibody.

Statistical analysis. Data for each condition are summarized as means ± SE, where the number of rats per treatment group is indicated in the legends of the figure or table. Unless otherwise indicated, statistical evaluation of the data was performed using 2-way ANOVA with post hoc Student-Newman-Keuls test when the interaction was significant. When necessary, data were logaritically transformed to normalize the distribution of residuals and to obtain variance homogeneity. Differences were considered significant when P < 0.05.

Results

Plasma amino acid and hormone concentrations. The administration of AICAR in control rats increased the plasma...
leucine concentration by 77% compared with time-matched values from Sal + Sal rats (Table 1). Provision of oral leucine increased the plasma leucine concentration to 3.7-fold of control values. The leucine concentrations achieved in the AICAR + Leu group did not differ from those in the Sal + Leu group.

AICAR increased the plasma concentrations of the other 2 branched-chain amino acids, isoleucine and valine, by 84% and 65%, respectively (Table 1). In control rats, oral leucine did not alter plasma isoleucine but decreased the valine concentration by 32%. The plasma concentrations of isoleucine and valine in the AICAR + Leu group were greater than those in the Sal + Leu rats.

AICAR alone decreased the plasma insulin concentration by 45% compared with time-matched values from control rats (Table 1). Conversely, leucine alone increased insulin 49% compared with control values. In contrast, no hyperinsulinemia was detected in rats in the AICAR + Leu group. Neither AICAR nor leucine significantly altered the plasma concentration of either insulin-like growth factor-1 or testosterone at the time point assessed (data not shown).

**Activation of AMPK, adenine nucleotide concentration, and protein synthesis in muscle.** AICAR administered in vivo activated AMPK in gastrocnemius as indicated by the increased Thr172 phosphorylation (control = 1.00 ± 0.07-fold vs. AICAR = 2.33 ± 0.36-fold of Sal control; *P < 0.05*). Furthermore, AICAR increased Ser79 phosphorylation of acetyl-CoA carboxylase, a well-established substrate of AMPK (control = 1.00 ± 0.11-fold vs. AICAR = 1.79 ± 0.21-fold of Sal control; *P < 0.05*).

The in vivo-determined rate of muscle protein synthesis was reduced 34% by AICAR (Fig. 1). Protein synthesis increased 28% in the Sal + Leu group compared with that of the Sal + Sal group. In contrast, leucine did not increase protein synthesis in gastrocnemius from AICAR-treated rats.

The AMP, ATP, and CP concentrations of gastrocnemius 1 h after the injection of AICAR did not differ from the time-matched controls (Table 2). Likewise, the adenine nucleotide concentration of muscle was not altered by the oral administration of leucine in either control or AICAR-treated rats. As a consequence, the AMP:ATP ratio in skeletal muscle, which is a sequence, the AMP:ATP ratio in skeletal muscle, which is a

**Alterations in mTOR signaling.** The kinase activity of mTOR was not directly examined, but a functional readout of its activity was determined by quantifying phosphorylation of 4E-BP1 and S6K1 at sites (Thr37/46 and Thr389, respectively) known to be phosphorylated by mTOR (27,28). AICAR decreased Thr37/46 phosphorylation of 4E-BP1 by 40% compared with values from the Sal + Sal group (Fig. 2A,E).

**Potential regulators of mTOR activity.** AICAR decreased TSC2 phosphorylation by 25% in gastrocnemius in control rats (Fig. 5A,E). However, this decreased TSC2 phosphorylation was

### Table 1

Plasma concentration of branched-chain amino acids and insulin in rats treated with AICAR, leucine, both, or neither

<table>
<thead>
<tr>
<th></th>
<th>Leucine</th>
<th>Isoleucine</th>
<th>Valine</th>
<th>Insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>μmol/L</td>
<td>μmol/L</td>
<td>pmol/L</td>
<td>pmol/L</td>
</tr>
<tr>
<td>Sal + Sal</td>
<td>165 ± 6±</td>
<td>57 ± 4±</td>
<td>118 ± 5±</td>
<td>547 ± 41±</td>
</tr>
<tr>
<td>AICAR + Sal</td>
<td>293 ± 16±</td>
<td>105 ± 4±</td>
<td>194 ± 10±</td>
<td>304 ± 44±</td>
</tr>
<tr>
<td>Sal + Leu</td>
<td>773 ± 45±</td>
<td>57 ± 6±</td>
<td>80 ± 5±</td>
<td>814 ± 93±</td>
</tr>
<tr>
<td>AICAR + Leu</td>
<td>968 ± 93±</td>
<td>82 ± 9±</td>
<td>142 ± 13±</td>
<td>160 ± 46±</td>
</tr>
</tbody>
</table>

1 Values are means ± SEM; *n* = 8–10. Means in a column without a common letter differ, *P < 0.05.*

### Table 2

Adenine nucleotide concentration in gastrocnemius from rats treated with AICAR, leucine, both, or neither

<table>
<thead>
<tr>
<th></th>
<th>AMP</th>
<th>ATP</th>
<th>CP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>μmol/L</td>
<td>pmol/g</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Sal + Sal</td>
<td>0.115 ± 0.007</td>
<td>7.51 ± 0.22</td>
<td>22.4 ± 1.1</td>
</tr>
<tr>
<td>AICAR + Sal</td>
<td>0.108 ± 0.005</td>
<td>7.72 ± 0.19</td>
<td>21.9 ± 1.2</td>
</tr>
<tr>
<td>Sal + Leu</td>
<td>0.112 ± 0.006</td>
<td>7.69 ± 0.24</td>
<td>23.7 ± 0.9</td>
</tr>
<tr>
<td>AICAR + Leu</td>
<td>0.111 ± 0.007</td>
<td>7.73 ± 0.18</td>
<td>23.5 ± 1.6</td>
</tr>
</tbody>
</table>

1 Values are means ± SEM; *n* = 8–10. There was no statistical difference among any of the 4 groups, as analyzed by ANOVA, for AMP, ATP, or CP.

**Conversely, oral leucine increased 4E-BP1 phosphorylation by 45% in control rats. In contrast, no such hyperphosphorylation of 4E-BP1 was detected in gastrocnemius of rats in the AICAR + Leu group.**

AICAR decreased both basal S6K1 phosphorylation and completely prevented the 3-fold leucine-induced increase (Fig. 2B,F). Comparable AICAR- and leucine-induced changes in the phosphorylation of other sites on S6K1 were observed with a phosphor-specific antibody for Thr421/Ser424 (data not shown). AICAR- and leucine-induced changes in the Ser240/Ser244-phosphorylation of the ribosomal protein S6 were comparable to the above mentioned changes in S6K1 (Fig. 2C).

AICAR alone decreased the active eIF4E-eIF4G complex by 65% in muscle from rats in the Sal + Sal group (Fig. 3A,D). Contrary to expectations, the inactive eIF4E-eIF4G complex did not significantly increase (Fig. 3B,E). Whereas leucine increased eIF4E-eIF4G and produced a reciprocal decrease in the formation of the eIF4E-4EBP1 complex in control rats, AICAR completely prevented the leucine-induced redistribution of eIF4E between the inactive eIF4E-4EBP1 and active eIF4E-eIF4G complex.

The basal level of eIF4G phosphorylation was not different between rats in the AICAR + Sal and Sal + Sal groups (Fig. 4A,C). However, AICAR essentially prevented the leucine-induced increase in Ser1108 phosphorylation of eIF4G. All of these changes were independent of a change in total eIF4G in muscle (Fig. 4B).

**FIGURE 1** Skeletal muscle (gastrocnemius) protein synthesis in rats treated with AICAR, leucine, both, or neither. Values in bar graph are means ± SEM; *n* = 8–10. Means without a common letter differ, *P < 0.05.* There was no difference in the dry:wet weight ratios of muscle from control and AICAR-treated rats (data not shown).

**Potential regulators of mTOR activity.** AICAR decreased TSC2 phosphorylation by 25% in gastrocnemius in control rats (Fig. 5A,E). However, this decreased TSC2 phosphorylation was...
not associated with a concomitant change in the amount of TSC1-TSC2 complex in response to AICAR (Fig. 5C). Addition-
ally, leucine did not significantly alter TSC2 phosphorylation or
TSC1/C1TSC2 binding in either the basal state or in rats treated with
AICAR.

The mTOR complex 1 (mTORC1), which is composed of at
least 4 proteins (mTOR, raptor, GβL, and PRAS40) was next
determined because of its predominant role in nutrient regulation
of protein synthesis (29). Western blot analysis of mTOR, raptor,
GβL, or PRAS40 in whole muscle homogenates did not change
for any of these 3 proteins in response to AICAR and/or leucine
(data not shown). However, the extent of Ser792 phosphorylated
raptor in muscle from AICAR + Sal rats was 2-fold that in the
Sal + Sal group; a similar increment was seen in the AICAR+
Leu group (Fig. 6A, C). Leucine alone did not significantly alter raptor
phosphorylation. As described above, this AICAR-induced
increase in raptor phosphorylation was independent of a change
in total raptor in tissue homogenates (Fig. 6B). Conversely,
AICAR decreased Thr246 phosphorylation of PRAS40 in muscle
homogenates from control rats (Fig. 6D, F). PRAS40 phosphory-
lation increased in the Sal + Leu group but not in AICAR-
treated rats and these changes were independent of an AICAR- or
leucine-induced change in total PRAS40 in muscle (Fig. 6E).

We did not detect any difference among the 4 groups in the
amount of mTOR, GβL, or PRAS40 bound to raptor, using
homogenization conditions that maintain protein-protein inter-
actions (data not shown). The association of raptor to mTOR was
also not changed when mTOR was immunoprecipitated and
raptor immunoblotted (data not shown). As a positive control,
we immunoprecipitated mTOR from muscle of rats treated with
rapamycin and reduced the interaction of raptor with mTOR by
85% (data not shown).

eEF2 phosphorylation. Select catabolic agents may also impair
protein synthesis via enhanced phosphorylation (Thr56) of eEF
and inhibition of translation elongation (30). However, at the
time point assessed, the phosphorylation of eEF2 in muscle
was not significantly altered by AICAR (control = 1.00 ± 0.11
arbitrary units vs. AICAR = 0.94 ± 0.08 arbitrary units). The
amount of total eEF2 was also not altered by either AICAR and/or
leucine (data not shown).
Discussion

The in vivo administration of AICAR and activation of AMPK decreases basal protein synthesis and largely prevents the increment expected in response to leucine in fast-twitch skeletal muscle. These responses are comparable to those in other stress conditions, such as sepsis and endotoxemia (3,6,7,15). In vivo-administered AICAR decreased 4E-BP1 phosphorylation in muscle under basal conditions. Although hypophosphorylated 4E-BP1 interacts more avidly with eIF4E than hyperphosphorylated forms of the protein (31), we did not observe a concomitant increase in the inactive eIF4E/eIF4G complex as anticipated. However, AICAR did markedly decrease the binding of eIF4E with eIF4G. Although we cannot explain this dichotomy, a change in eIF4E/eIF4G without a reciprocal change in eIF4E phosphorylation was not expected under conditions where both 4E-BP1 and S6K1 phosphorylation was reduced. Although the reason for this apparent discrepancy is currently unclear, such a differential response has been reported at early time points in myocytes treated with AICAR (13).

A possible mechanism by which AMPK might cause mTOR dysregulation involves its inhibition of AKT-dependent phosphatase activity of TSC2 and/or the binding of TSC2 with its homolog TSC1, which increases the binding of GDP to Ras homolog enriched in brain (Rheb) and thereby inhibits mTOR activity. Previous studies using cultured myocytes have demonstrated such changes in TSC2 (13). However, under in vivo conditions, AMPK activation in muscle resulted in a relatively small decrease in TSC2 phosphorylation under basal conditions and this change was not associated with a change in either TSC1-TSC2 binding or the total amount of TSC1 or TSC2 protein.

Alternatively, mTOR activity can be regulated by its binding to various proteins, including raptor, which is sensitive to nutrient and hormonal regulation (29). Incubation of cultured myocytes with AICAR increases the binding of raptor to mTOR (13), which may imply AICAR promotes a “closed conformation” in the mTOR-raptor complex, rendering it less active. However, in other cells, AICAR does not alter mTOR-raptor complex function (35) and whether raptor enhances or represses mTOR activity remains controversial (36,37). Regardless, our present data fail to confirm any change in mTOR raptor binding in skeletal muscle in response to AICAR. Furthermore, there was no AICAR-induced change in either the total amount of Gβλ, a positive regulator of mTOR activity (38), or its binding to mTORC1.

The mTORC1 complex also binds PRAS40 via its interaction with raptor (39,40). Overexpression of PRAS40 inhibits mTOR autophosphorylation and kinase activity. However, the ability of in vivo administered AICAR to inhibit basal muscle protein synthesis was not associated with a change in either the total amount of PRAS40 or its binding with raptor in the mTORC1. PRAS40 is also a phospho-protein and the extent of its phosphorylation is inversely proportional to the concentration of PRAS40 (39,40), suggesting PRAS40 is also a downstream substrate for mTOR. Our data showing that AICAR decreases basal PRAS40 phosphorylation are consistent with this view.
Recently, AICAR-induced activation of AMPK in myocytes and other cells has been reported to increase the phosphorylation of raptor via a TSC2-independent mechanism and thereby impair mTORC1 kinase activity (35). In the current study, the leucine-induced stimulation of muscle protein synthesis was not associated with a change in raptor phosphorylation. However, AICAR markedly increased Ser792 phosphorylation of raptor in muscle of control rats. Because raptor phosphorylation was similarly increased in both control + AICAR and Leu + AICAR rats, the enhanced phosphorylation of this mTORC1 complex protein remains a possible mechanism by which AICAR produces leucine resistance in skeletal muscle.

In addition to its role as a precursor molecule, leucine also regulates protein synthesis by activating intracellular signaling pathways stimulating translation initiation (40). Our current data, which show increased phosphorylation of 4E-BP1, S6K1, S6, and eIF4G as well as increased eIF4E-eIF4G complex after leucine, are consistent with reports indicating stimulation in cap-dependent translation and mTOR activity (21). However, increased mTOR activity could not be ascribed to a change in mTOR-raptor binding, phosphorylation of raptor, or the association of PRAS40 with raptor. The inability of amino acids to alter PRAS40-raptor binding in cultured cells has been reported and differs from the marked decrease in PRAS40-raptor seen in insulin-treated cells (39). Furthermore, oral administration of leucine to rats also did not alter TSC2 phosphorylation or its binding with TSC1, results consistent with studies showing that nutrients can activate mTOR by a TSC-independent pathway (41).

Several catabolic conditions, including sepsis, alcohol abuse, and glucocorticoid excess in aged rats, produce a leucine resistance in striated muscle (3,6–10). AICAR also prevents mTOR activation and hypertrophy in cardiac muscle in response to pressure overload (17) and in skeletal muscle following electrical stimulation (16). Our results indicate that AICAR-induced activation of AMPK also antagonizes the normal protein anabolic response to leucine. The ability of AICAR to produce leucine resistance is associated with inhibition of mTOR activity, as evidenced by the failure of leucine to enhance 4E-BP1 and S6K1 phosphorylation. Further, this AICAR-induced decrement in 4E-BP1 phosphorylation seems the likely cause for the inability of leucine to alter the distribution of eIF4E between the active and inactive complexes. Moreover, AICAR essentially prevented the ability of leucine to increase eIF4G phosphorylation. A similar reduction in leucine-stimulated eIF4G phosphorylation has been reported in muscle of rats given the mTOR inhibitor rapamycin (42). Conversely, the AICAR-induced decrement in mTOR activity could not be attributed to a change in TSC2 phosphorylation, the binding of TSC2 with TSC1, or to the amount of mTOR-raptor or PRAS40-raptor complex. It remains possible that AICAR caused leucine resistance by impairing the subsequent movement of the mTOR-raptor complex to the eIF3-preinitiation complex or via activation of human vacuolar protein sorting (hVps)-34, which is a class III phosphatidylinositol 3-kinase (43); however, these possibilities were not pursued in the current investigation.

The ability of AICAR to inhibit protein synthesis appears to be mediated primarily by inhibition of translation initiation, because in this study, AICAR did not alter the expression or phosphorylation of eEF2. Hyperphosphorylation of eEF2 renders this protein inactive and thereby inhibits protein synthesis (30). However, our data are in apparent contrast to those reported in rat muscle 40 min after AICAR administration (16). The difference between our study and this earlier report may be related to the relatively transient effect of AICAR on this particular parameter. This is exemplified by in vitro studies showing AICAR increases eEF2 phosphorylation time dependently, with eEF2 phosphorylation increased at 15–30 min but comparable to basal levels at 60 min (13).

The AICAR-induced decrease in muscle protein synthesis also could not be attributed to a difference in the circulating concentrations of the branched-chain amino acids. Leucine, isoleucine, and valine concentrations were as high in AICAR + Leu rats as in the Sal + Leu rats. However, AICAR attenuated the leucine-induced hyperinsulinemia. Therefore, the lack of a permissive effect of insulin with leucine in the AICAR + Leu-treated rats might partially explain the inability of muscle protein synthesis to increase after AICAR. The role of the transient leucine-induced hyperinsulinemia in mediating the anabolic effect of leucine on muscle protein synthesis is currently unclear [see discussion in (44)] and the relative importance of this diminished insulin response in AICAR-treated rats compared with a direct effect on muscle per se will need to be defined in

<FIGURE 6> Phosphorylation of raptor and PRAS40 in gastrocnemius of rats treated with AICAR, leucine, both, or neither. Representative Western blots of total (A) and phosphorylation raptor (Ser792) (B) in whole muscle homogenates and quantitation of densitometric analysis of all immunoblots for phosphorylated raptor (C). Representative Western blot of total (D) and phosphorylated (Thr246) (E) PRAS40 in whole muscle homogenates and quantitation of densitometric analysis of all immunoblots for phosphorylated raptor (F). For bar graphs, the value from the Sal + Sal group was set at 1.0. Values in bar graph are means ± SEM; n = 8–10. Means without a common letter differ, P < 0.05.
future studies. However, it is noteworthy that AICAR has been shown to inhibit both basal and leucine-stimulated mTOR activity in cultured myocytes (18), suggesting that at least a portion of the AICAR effect is mediated directly within muscle.

Finally, previous studies in myoblasts suggested the ability of leucine to stimulate protein synthesis is mediated by decreased AMPK activity resulting from a concomitant elevation in the ATP concentration (18). However, such an effect of leucine on AMPK activity and ATP concentration in skeletal muscle under in vivo conditions was not observed in the current study. Therefore, whereas the anabolic effect of leucine on mTOR-stimulated protein synthesis appears mediated via a suppression of AMPK activity in myoblasts incubated under conditions of low serum and energy substrates, such a mechanism is clearly not operational in skeletal muscle under in vivo conditions.

In conclusion, we describe herein that stimulation of AMPK activity by the chemical activator AICAR produces a muscle leucine resistance under in vivo conditions. The diminution of the anabolic response to leucine by AICAR is associated with a reduction in mTOR activity (evidenced by the decreased phosphorylation of 4E-BP1, S6K1, elf4E, and PRAS40), maintained enhanced raptor phosphorylation, and a reduction in the active elf4E elf4F4G complex. Moreover, these changes were independent of changes in TSC2 phosphorylation, TSC1-TSC2 heterodimer formation, and the binding of either mTOR or PRAS40 with raptor. Finally, our data suggest that some mechanisms regulating mTOR activity in cell culture may not necessarily be operational under in vivo conditions.

Literature Cited


